Article

MAPK/ERK signalling mediates VEGF‐induced bone marrow stem cell differentiation into endothelial cell

Journal of Cellular and Molecular Medicine (Impact Factor: 3.7). 02/2008; 12(6a):2395 - 2406. DOI: 10.1111/j.1582-4934.2008.00266.x

ABSTRACT Multi-potent adult progenitor cells (MAPCs) differentiate into endothelial cells (ECs) in the presence of vascular endothelial growth factor (VEGF). The mechanism(s) of VEGF-induced differentiation of MAPCs to ECs are not yet known. We, therefore, examined the role of mitogen-activated protein kinase/extracellular signal-regulated kinase (p42/44-MAPK/ERK1/2) signalling in endothelial differentiation from bone marrow stem cells. We observed that VEGF stimulation of MAPCs for 14 days results in a significant expression of endothelial-specific gene and/or proteins including von Willebrand factor (vWF), vascular endothelial-cadherin (VE-cadherin), VEGF receptor-2 (VEGFR2), and CD31. Up-regulation of EC-specific markers was accompanied by a cobblestone morphology, expression of endothelial nitric oxide synthase (eNOS), and Dil-Ac-LDL uptake, typical for EC morphology and function. VEGF induced a sustained activation of p42 MAPK/ERK, but not that of p44 MAPK/ERK during the course of MAPCs differentiation in a time-dependent manner up to 14 days. VEGF-induced activation of p42 MAPK/ERK also led to the nuclear translocation of MAPK/ERK1/2. Incubation of MAPCs with MAPK/ERK1/2 phosphorylation inhibitor PD98059 blocked the sustained VEGF-induced MAPK/ERK1/2 phosphorylation as well as its nuclear translocation in the differentiating MAPCs. Inhibition of MAPK/ERK1/2 phosphorylation by PD98059 also blocked the expression of EC-specific genes in these cells and their differentiation to ECs. These data suggest that VEGF induces MAPC differentiation into EC via a. MAPK/ERK1/2 signalling pathway-mediated mechanism in vitro.

0 Followers
 · 
177 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A low-efficiency yield hinders the use of stem cells as a source of endothelial cells (ECs) for therapeutic vascularization, and the diversity of the transforming growth factor-β (TGF-β) superfamily has undermined understanding the effects of its potent vascularization-inducing. Herein, we studied the role of the TGF-β superfamily in EC differentiation of rat bone marrow mesenchymal stem cells (MSCs) induced by Smad2/3 and Smad1/5/8 signaling. MSCs that had been sorted by flow cytometry as CD31-negative were cultured for 14 days in medium supplemented with vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) as the control. The Smad2/3 pathway was activated by TGF-β1 and Smad1/5/8 by bone morphogenetic proteins (BMPs). In the early phase in the Smad2/3-activated group, there were 10% CD31-positive cells, which was significantly higher than in the control group. A low Smad1/5/8 phosphorylation level after BMP4 activation doubled the number of CD31-positive cells, while a higher phosphorylation level after BMP9 activation showed no effect. A Smad2/3 inhibitor initially blocked differentiation but later promoted it, while a Smad1/5/8 inhibitor reversed the induction observed with BMPs. Moreover, the positive effects of R-Smad on differentiation were weakened by the VEGF neutralizing antibody. And a Smad3 inhibitor decreased VEGF expression and blocked differentiation in both the early and late phases. In conclusion, differentiation of ECs from MSCs via Smad2/3 signaling is stage dependent. Activation, particularly by Smad3, significantly promotes differentiation at an early phase but later is suppressive. A low Smad1/5/8 phosphorylation level has a positive effect, and R-Smad effects are partly mediated by VEGF.
    Stem Cells and Development 01/2015; 24(11). DOI:10.1089/scd.2014.0253 · 4.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Increased levels of angiotensin II (Ang II) and activity of Ang II receptor type 1 (AT1R) elicit detrimental effects in cardiovascular disease. However, the role of Ang II receptor type 2 (AT2R) remains poorly defined. Mesenchymal stem cells (MSCs) replenish and repair endothelial cells in the cardiovascular system. Herein, we investigated a novel role of angiotensin signaling in enhancing vascular endothelial growth factor (VEGF)-A-mediated differentiation of MSCs into endothelial cells (ECs). Bone marrow was aspirated from the femurs of Yucatan microswine. MSCs were extracted via ficoll density centrifugation technique and were strongly immunopositive for MSC markers, CD44, CD90, and CD105, but negative for hematopoietic markers, CD14 and CD45. Subsequently, naive MSCs were differentiated for 10 days in varying concentrations and combinations of VEGF-A, Ang II, and AT1R or AT2R antagonists. Markers specific to ECs were determined by FACS analysis. AT1R and AT2R expression and cellular localization was demonstrated in MSCs stimulated with VEGF-A and Ang II via quantitative RT-PCR and immunofluorescence, respectively. Differentiation of naive MSCs in media containing Ang II (2 ng/ml) plus low-dose VEGF-A (2 ng/ml) produced a significantly higher percentage of cells that were positive for expression of EC markers (for example, Platelet endothelial cell adhesion molecule, vascular endothelial Cadherin and von Willebrand factor) compared to VEGF-A alone. Ang II alone failed to induce EC marker expression. MSCs differentiated with the combination of Ang II and VEGF-A were capable of forming capillary tubes using an in vitro angiogenesis assay. Induction of EC marker expression was greatly attenuated by co-treatment of Ang II/VEGF-A with the AT2R antagonist PD123319, but not the AT1R antagonist telmisartan. We report the presence of functional AT2R receptor on porcine bone marrow-derived MSCs, where it positively regulates EC differentiation. These findings have significant implications toward therapeutic approaches based on activation of AT2R, which could be a means to stimulate regeneration of damaged endothelium and prevent vascular thrombosis.
    Stem Cell Research & Therapy 01/2015; 6(1):4. DOI:10.1186/scrt538 · 4.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) have the capacity to restore liver function by differentiating into hepatocyte like cells. However, the underlying mechanisms are not well understood. Here, we have investigated the signals involved in the hepatic differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs). hUCMSCs were treated with mouse fetal liver-conditioned medium (FLCM) to induce hepatic differentiation. Flow cytometry, reverse transcription PCR, real-time PCR, immunocytochemistry, and polymerase chain reaction (PCR) array were used to detect the expression of MSC- and hepotocyte-specific markers in FLCM-treated hUCMSCs. Urea production and cytochrome P450 3A4 (CYP3A4) activity were used as indicators to evaluate liver cell characteristics. Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) was analyzed in hUCMSCs by Western blotting. Following FLCM treatment, expression of MSC-specific markers decreased, while hepatocyte-specific gene expression was increased. Urea production, albumin secretion, glycogen storage, and CYP3A4 activity were significantly enhanced in FLCM-treated cells. In addition, ERK1/2 phosphorylation was increased in a time-dependent manner through Raf/MEK/ERK pathway, and phosphorylation was sustained at a high level during hepatic induction. Inhibition of ERK1/2 activation by U0126 (an ERK1/2 inhibitor) and pFLAG-CMV-ERK1(K71R) (negative mutant of ERK1) reversed the expression of liver-specific genes in hUCMSCs and affected hepatic function significantly. In summary, this work shows that ERK1/2 phosphorylation plays an important role in inducing hepatic differentiation of hUCMSCs in FLCM. © 2015 by the Society for Experimental Biology and Medicine.
    Experimental Biology and Medicine 01/2015; 240(4). DOI:10.1177/1535370214548996 · 2.23 Impact Factor

Preview

Download
1 Download